PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients with esophageal cancer remains unsatisfactory, with a 5-year overall survival rate below 20%. As an effective modality for local disease control, local radiotherapy has no established optimal sequencing schedule when combined with systemic therapy. The timing of radiotherapy intervention may directly affect treatment efficacy, treatment tolerance and quality of life of patients. Several studies have explored the impact of radiotherapy timing in oligometastatic ESCC, yet substantial limitations persist in current evidence, resulting in a lack of unified guideline recommendations and wide heterogeneity in clinical practice. Most existing investigations are retrospective or small-sample prospective studies with high heterogeneity in study design, patient population selection and treatment regimens, yielding inconsistent conclusions that cannot support consistent clinical consensus. To clarify the impact of radiotherapy timing on clinical efficacy in oligometastatic esophageal cancer, the investigator designed the present clinical trial. This study aims to compare the efficacy and safety of concurrent radiotherapy versus sequential radiotherapy on the basis of immunochemotherapy among patients with oligometastatic ESCC, so as to fill the evidence gap in existing research.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza raka przełyku (typ płaskopątkowy)
- •Przerzuty w maksymalnie czterech miejscach w organizmie, maksymalnie trzy w jednym organie, każde nie większe niż 5 cm
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-1)
- •Wystarczająco dobre funkcje wątroby, nerek, krwi i krzepnięcia
- •Nie przyjmowana wcześniej immunoterapia (z pewnymi wyjątkami)
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Podejrzenie lub potwierdzona przetoka przełyku
- •Wznowa nowotworu w polu poprzedniej radioterapii
- •Aktywna infekcja wymagająca leczenia
- •Aktywna choroba autoimmunologiczna wymagająca leczenia
- •Immunodeficyt lub niedawne przyjmowanie leków immunosupresyjnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fudan University Shanghai cancer center
Shanghai, China
Trial contact
Guangmin Mao
Kuaile Zhao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.